TY - JOUR
T1 - Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice.
AU - Biscetti, Federico
AU - Pitocco, Dario
AU - Straface, Giuseppe
AU - Zaccardi, Francesco
AU - De Cristofaro, Raimondo
AU - Rizzo, Paola
AU - Lancellotti, Stefano
AU - Arena, Vincenzo
AU - Stigliano, Egidio
AU - Musella, Tittania
AU - Ghirlanda, Giovanni
AU - Flex, Andrea
PY - 2011
Y1 - 2011
N2 - The aim of the present study was to investigate the role of GV (glycaemic variability) in diabetic vascular complications and to explore the molecular pathways modulated by glycaemic 'swings'. We developed a murine model. A total of 30 diabetic mice received once daily basal insulin administration plus two oral boluses of glucose solution (GV group, named 'V') and 30 diabetic mice received once daily basal insulin plus two oral boluses of saline solution (stable hyperglycaemia group, named 'S') for a period of 30 days. Glycaemia was measured eight times daily to detect GV. Finally, postischaemic vascularization, induced by hindlimb ischaemia 30 days after diabetes onset, was evaluated. We found that GV was significantly different between S and V groups, whereas no significant difference in the mean glycaemic values was detected. Laser Doppler perfusion imaging and histological analyses revealed that the ischaemia-induced angiogenesis was significantly impaired in V mice compared with S group, after ischaemic injury. In addition, immunostaining and Western blot analyses revealed that impaired angiogenic response in V mice occurred in association with reduced VEGF (vascular endothelial growth factor) production and decreased eNOS (endothelial nitric oxide synthase) and Akt (also called protein kinase B) phosphorylation. In conclusion, we describe a murine model of GV. GV causes an impairment of ischaemia-induced angiogenesis in diabetes, likely to be independent of changes in average blood glucose levels, and this impaired collateral vessel formation is associated with an alteration of the VEGF pathway.
AB - The aim of the present study was to investigate the role of GV (glycaemic variability) in diabetic vascular complications and to explore the molecular pathways modulated by glycaemic 'swings'. We developed a murine model. A total of 30 diabetic mice received once daily basal insulin administration plus two oral boluses of glucose solution (GV group, named 'V') and 30 diabetic mice received once daily basal insulin plus two oral boluses of saline solution (stable hyperglycaemia group, named 'S') for a period of 30 days. Glycaemia was measured eight times daily to detect GV. Finally, postischaemic vascularization, induced by hindlimb ischaemia 30 days after diabetes onset, was evaluated. We found that GV was significantly different between S and V groups, whereas no significant difference in the mean glycaemic values was detected. Laser Doppler perfusion imaging and histological analyses revealed that the ischaemia-induced angiogenesis was significantly impaired in V mice compared with S group, after ischaemic injury. In addition, immunostaining and Western blot analyses revealed that impaired angiogenic response in V mice occurred in association with reduced VEGF (vascular endothelial growth factor) production and decreased eNOS (endothelial nitric oxide synthase) and Akt (also called protein kinase B) phosphorylation. In conclusion, we describe a murine model of GV. GV causes an impairment of ischaemia-induced angiogenesis in diabetes, likely to be independent of changes in average blood glucose levels, and this impaired collateral vessel formation is associated with an alteration of the VEGF pathway.
KW - Glycaemic variability
KW - angiogenesis
KW - diabetes complication
KW - endothelial nitric oxide synthase
KW - vascular endothelial growth factor
KW - Glycaemic variability
KW - angiogenesis
KW - diabetes complication
KW - endothelial nitric oxide synthase
KW - vascular endothelial growth factor
UR - http://hdl.handle.net/10807/4896
U2 - 10.1042/CS20110043
DO - 10.1042/CS20110043
M3 - Article
SN - 0143-5221
VL - 121
SP - 555
EP - 564
JO - Clinical Science
JF - Clinical Science
ER -